Alpha-1 Antitrypsin Deficiency Treatment Market Upcoming Trends and Analysis Report 2023 to 2033Posted by Ganesh Shinde on January 30th, 2023 The global Alpha-1 antitrypsin deficiency market is expected to be worth US$ 3 billion in 2023, rising to US$ 10 billion at a CAGR of 12.8% from 2023 to 2033. One of the primary factors driving market expansion is the rising prevalence of respiratory illnesses. Additionally, increased use of augmentation treatment is driving market growth. The primary drivers driving market growth are technological advancements, increased R&D spending, and the increasing prevalence of target illnesses. Investments in research and development (R&D) are also expected to have a significant impact on the industry. Several companies are attempting to build a transformative portfolio by leveraging in-house capabilities and expanding those capabilities through strategic alliances, R&D expansion, and prospective licencing, merger, and acquisition activities. Key Takeaways from the Market Study
ARO-AAT (Arrowhead Pharmaceutical) is a second-generation subcutaneously administered drug that inhibits hepatic synthesis of the mutant AAT protein by silencing the alpha-1 antitrypsin (AAT) gene transcript. The company is currently conducting Phase II clinical trials to evaluate the drug's safety, tolerability, and pharmacodynamic impact in AATD patients. Key players in the Alpha-1 Antitrypsin Deficiency (A1ATD) market are:
Browse More@ https://www.futuremarketinsights.com/reports/alpha-1-antitrypsin-deficiency-market Key Segments Profiled in the Alpha-1 Antitrypsin Deficiency Market Industry Survey By Product Type:
By Application:
Like it? Share it!More by this author |